TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Childhood Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy
Brief Summary: This is a prospective interventional study involving young children who will all receive non-invasive, passive assessments of sensory and motor function. In addition a subpopulation of young children with cerebral palsy will participate in a randomized controlled trial of constraint-induced movement therapy, a routinely prescribed therapy used in clinical practice for children with motor difficulties. The study attempts to apply a rigorous scientific approach to study a widely used but poorly studied practice. The design is an RCT with wait-list controls to allow all children to benefit from the therapy, even if they are randomized to the control group. All children, regardless of group allocation will continue with their standard of care occupational and physical therapy throughout the study.


Options:
A: Arm Label: Constraint-induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Arm Label: Transditional rehabilitation; Type: OTHER; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Intervention Type: BEHAVIORAL; Name: Modified Constraint-induced Movement Therapy; Assigned to Arm(s): Constraint-induced Movement Therapy, Transditional rehabilitation
B: Arm Label: Experimental CIMT; Type: EXPERIMENTAL; Interventions: Device: Constraint induced movement therapy (CIMT) | Arm Label: Active Play; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: play | Intervention Type: DEVICE; Name: Constraint induced movement therapy (CIMT); Assigned to Arm(s): Experimental CIMT | Intervention Type: BEHAVIORAL; Name: play; Assigned to Arm(s): Active Play
C: Arm Label: CIMT Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Constraint-Induced Movement Therapy (CIMT) | Arm Label: HABIT Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) | Intervention Type: PROCEDURE; Name: Constraint-Induced Movement Therapy (CIMT); Assigned to Arm(s): CIMT Intervention | Intervention Type: PROCEDURE; Name: Hand-Arm Bimanual Intensive Therapy (HABIT); Assigned to Arm(s): HABIT Intervention
D: Intervention Type: BEHAVIORAL; Name: Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phone-based Intervention Under Nurse Guidance After Stroke
Brief Summary: This research seeks to develop a culturally-acceptable, effective, and sustainable way of utilizing the rapidly growing penetration of mobile phones among people in Sub-Saharan Africa (SSA), to improve the currently poor control of hypertension among patients at high risk for future stroke. It also aims to develop human capital in SSA to conduct locally-relevant, high-quality stroke research in the future. Specifically, this study will preliminarily test a strategy that incorporates mobile phone texting and home blood pressure monitoring directed by trained nurses, to improve patient adherence to proven medical therapies for treating hypertension.


Options:
A: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program
B: Arm Label: Regular care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Support program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient centered structured support program | Intervention Type: BEHAVIORAL; Name: Patient centered structured support program; Assigned to Arm(s): Support program
C: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Smart-phone based technology | Arm Label: Usual background care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smart-phone based technology; Assigned to Arm(s): Behavioral
D: Arm Label: 1: Care management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: 2: Written Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): 1: Care management | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): 2: Written Materials

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Low-Level Laser Therapy (LLLT) Effectiveness in Accelerating Orthodontic Tooth Movement For Dental Crowding Cases: A Randomized Controlled Clinial Trial
Brief Summary: 26 participants from the Orthodontic Department at University of Damascus Dental School will be randomly assigned into two groups. In the experimental group, a low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 j per each tooth. Control group will undergo typical orthodontic treatment with the laser device applied the same manner but without being turned on (to get the placebo effect for pain reduction effect). This procedure will be repeated after 3, 7, 14 days and each 15 days from the beginning of the second month till the end of the leveling and alignment stage.


Options:
A: Arm Label: Vibration Device+Fixed Appliance Tx; Type: EXPERIMENTAL; Interventions: Device: Vibration Device | Arm Label: No Vibration Device+Fixed Appliance Tx; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibration Device; Assigned to Arm(s): Vibration Device+Fixed Appliance Tx
B: Arm Label: 0.018 bracket slot system; Type: EXPERIMENTAL; Interventions: Device: Orthodontic bracket slot system | Arm Label: 0.022 bracket slot system; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthodontic bracket slot system | Intervention Type: DEVICE; Name: Orthodontic bracket slot system; Assigned to Arm(s): 0.018 bracket slot system, 0.022 bracket slot system
C: Arm Label: Conventional Decrowding; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Level Laser Therapy; Type: EXPERIMENTAL; Interventions: Radiation: low level laser therapy | Intervention Type: RADIATION; Name: low level laser therapy; Assigned to Arm(s): Low Level Laser Therapy
D: Arm Label: OrthoAccel Device; Type: EXPERIMENTAL; Interventions: Device: OrthoAccel Device | Arm Label: Sham Device (inactive device); Type: SHAM_COMPARATOR; Interventions: Device: Sham Device | Intervention Type: DEVICE; Name: OrthoAccel Device; Assigned to Arm(s): OrthoAccel Device | Intervention Type: DEVICE; Name: Sham Device; Assigned to Arm(s): Sham Device (inactive device)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is a condition where accumulation of fat in the liver leads to metabolic dysfunction. Currently there are no approved treatments for NAFLD. Part of the metabolic dysfunction may arise through changes in the gut microbiota. Prebiotic fibres have beneficial effects on glucose tolerance, body weight, and gut microbiota; therefore they may have potential as part of a dietary strategy for NAFLD treatment.


Options:
A: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish oil, Placebo
C: Arm Label: Prebiotic Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic fibre, Behavioral: Weight Loss | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Weight Loss | Arm Label: Weight Loss; Type: OTHER; Interventions: Behavioral: Weight Loss | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic fibre; Assigned to Arm(s): Prebiotic Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Placebo, Prebiotic Fibre, Weight Loss
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)
Brief Summary: The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared to standard initiation, leads to:

1. Improved survival (primary outcome); and
2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days


Options:
A: Arm Label: Early RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Early RRT strategy | Arm Label: Delayed RRT strategy; Type: EXPERIMENTAL; Interventions: Procedure: Delayed RRT strategy | Intervention Type: PROCEDURE; Name: Early RRT strategy; Assigned to Arm(s): Early RRT strategy | Intervention Type: PROCEDURE; Name: Delayed RRT strategy; Assigned to Arm(s): Delayed RRT strategy
B: Arm Label: Standard RRT initiation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard RRT initiation | Arm Label: Accelerated RRT initiation; Type: EXPERIMENTAL; Interventions: Other: Accelerated RRT initiation | Intervention Type: OTHER; Name: Standard RRT initiation; Assigned to Arm(s): Standard RRT initiation | Intervention Type: OTHER; Name: Accelerated RRT initiation; Assigned to Arm(s): Accelerated RRT initiation
C: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
D: Arm Label: early group; Type: EXPERIMENTAL; Interventions: Procedure: continuous renal replacement therapies | Arm Label: delayed group; Type: EXPERIMENTAL; Interventions: Procedure: continuous renal replacement therapies | Intervention Type: PROCEDURE; Name: continuous renal replacement therapies; Assigned to Arm(s): delayed group, early group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ART and Hall Technique for the Management of Occlusal-proximal Caries in Primary Molars: A Randomized Clinical Trial
Brief Summary: The aim of this, two-arm, parallel group, patient-randomised controlled, superiority trial is to evaluate the survival rate of approximal Atraumatic Restorative Treatment (ART) restorations compared to the Hall Technique (HT) placed in a school setting. The investigators will recruit 120 schoolchildren (5-10 years) with at least one occlusal-proximal carious lesion in primary molar. They will be randomized and treated following best-practice protocols to either receive an ART restoration using the high-viscosity glass ionomer cement (EQUIA Forte, capsules, GC Corp.) or a preformed metal crown placed using the HT (3M ESPE) cemented with glass ionomer luting cement (Fuji I Capsules, GC Corp.). Baseline measures and outcome data (at reviews over a three year period) will be assessed through participant report, clinical examination and parent report/ questionnaires.


Options:
A: Arm Label: Treatment with Infiltrant/Adhesive; Type: EXPERIMENTAL; Interventions: Drug: Resin infiltration / adhesive | Arm Label: Placebo, placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Resin infiltration / adhesive; Assigned to Arm(s): Treatment with Infiltrant/Adhesive | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, placebo treatment
B: Arm Label: SW intervention; Type: EXPERIMENTAL; Interventions: Procedure: SW | Arm Label: DCE intervention; Type: OTHER; Interventions: Procedure: DCE | Intervention Type: PROCEDURE; Name: SW; Assigned to Arm(s): SW intervention | Intervention Type: PROCEDURE; Name: DCE; Assigned to Arm(s): DCE intervention
C: Arm Label: Atraumatic Restorative Treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atraumatic Restorative Treatment | Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Intervention Type: PROCEDURE; Name: Atraumatic Restorative Treatment; Assigned to Arm(s): Atraumatic Restorative Treatment | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique
D: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Device: self assembling peptide P11-4 (Curodont™ Repair), Device: fluoride varnish (Duraphat®) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: fluoride varnish (Duraphat®) | Intervention Type: DEVICE; Name: self assembling peptide P11-4 (Curodont™ Repair); Assigned to Arm(s): intervention | Intervention Type: DEVICE; Name: fluoride varnish (Duraphat®); Assigned to Arm(s): control, intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
B: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
C: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
D: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
D: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: Healthy Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): Active, Healthy Control | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): Control
C: Arm Label: Standard treatment + cognitive remediation; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive remediation, Behavioral: Standard treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive remediation; Assigned to Arm(s): Standard treatment + cognitive remediation | Intervention Type: BEHAVIORAL; Name: Standard treatment; Assigned to Arm(s): Standard treatment, Standard treatment + cognitive remediation
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B

Answer: A